India: National List Of Essential Medicines, 2015- An Approach To Control Sale Price


The Core-Committee (Committee) constituted by the Ministry of Health & Family Welfare (MOHFW), Government of India, reviewed and revised the National List of Essential Medicines(NLEM),2011 and formulated the criteria for inclusion and deletion of medicines in National List of Essential Medicines based upon the directions to look into the matter of coronary stents directed by Hon'ble High Court of Delhi in the Writ Petition No 1772 of 2015 wherein petitioner filed PIL seeking a direction to the respondents to include coronary stents in the National List of Essential Medicines (NLEM) thereby controlling the sale price of the same.

Findings of the Committee

Upon the detailed examination, the Committee came to know that all the medicines are not listed in the National List of Essential Medicines (NLEM), 2011. The Committee opined that all medicines are essential and is taken only when it is needed by the patient and all these medicines, including life saving drugs, should be available in the market at affordable price. To keep this in view, the Committee recommended that the scope of price control needs to be enlarged to make all the drugs available, especially life saving drugs. Expressing concern over large sum of money spent on importing pharmaceutical products, the panel also called for incentivising domestic bulk drug industry and discourages Indian firms from buying from overseas. The report of the Committee addressed the topics pertaining to concept of essential medicines, criteria's considered for framing the NLEM and the necessity of revising the NLEM on a regular basis due to changing disease burden profile, emergence of antimicrobial resistance, development of newer and better medicines to preserve NLEM's relevance. NLEM has been revised twice the last being in 2011 and Committee recommended the revision of it at every three years.

Salient Feat ures of NLEM 2015

There were 348 medicines listed in NLEM, 2011. A total of 106 medicines have been added, and 70 medicines have been deleted to prepare NLEM, 2015 which now contains a total of 376 medicines. Medicines in NLEM, 2015 are listed with reference to the levels of healthcare, namely, Primary (P), Secondary (S) and Tertiary (T) because the treatment facilities, training, experience and availability of health care personnel differ at these levels. There are 209 medicine formulations listed for all levels of health care (P, S, T),115 medicine formulations for secondary and tertiary levels (S, T) and 79 medicine formulations for the tertiary level (T). It is to be noted that formulations of certain medicines are listed at different levels but as item, they are counted as one. The total number of medicines remains 376. The essentiality of a medicine has been considered in terms of its dosage form and strength also. In general, medicines have been mentioned with respect to their active moieties, without mentioning the salts. The NLEM, 2015 has been prepared adhering to the basic principles of Efficacy, Safety, Cost- Effectiveness and considering of diseases as public health problems in India.

What is an Essential Medicine

As per the World Health Organization, Essential Medicines1 are those that satisfy the priority health care needs of the population. The list is made with consideration to disease prevalence, efficacy, safety and comparative cost-effectiveness of the medicines. Such medicines are intended to be available in adequate amounts, in appropriate dosage forms and strengths with assured quality. They are available in the market such a way that an individual or community can afford. The concept of essential medicines revolves around addressing "priority health care needs" specific to a country. It is therefore important to take into consideration the 'burden' of diseases in that population. The burden of a disease may vary from country to country, so do the priority health care needs. For example, tuberculosis, malaria and diarrheal diseases are priority health care concerns in lowand middle- income countries, but it may not be so for high- income countries. On the same lines, trypanosomiasis may be a priority health care concern in the African region where it is endemic but not so in India.

Criteria Considered For Inclusion of A Medicine Into NLEM, 2015

For inclusion of a medicine into NLEM, 2015, certain criteria were considered such as medicine to be licensed and approved in the country by Drugs Controller General (India); medicine to be useful in disease which is a public health problem in India; medicine have proven efficacy and safety profile based on valid scientific evidence; medicine to be comparatively cost effective; medicine aligned with the current treatment guidelines for the disease; medicine to be stable under the storage conditions in India2. In addition to these criterias, other criteria were also considered such as, when more than one medicine are available from the same therapeutic class, preferably one prototype, medically best suited medicine of that class to be included after due deliberation and careful evaluation of their relative safety, efficacy, cost-effectiveness; price of total treatment is considered and not the unit price of a medicine; Fixed Dose Combinations are not included unless the combination has unequivocally proven advantage over single compounds administered separately, in terms of increasing efficacy, reducing adverse effects and/or improving compliance; the medicine in NLEM, 2015 are based at primary/ secondary/tertiary level of health care according to treatment facilities and training, experience and availability of health care personnel at these levels.

Criteria Considered For Deletion of A Medicine Into NLEM, 2015

Deletion of any medicine from the NLEM is based on certain conditions like the medicine has been banned in India; existence of reports of concerns on the safety profile of a medicine; if medicine with better efficacy or favourable safety profile and better cost-effectiveness is available; the disease burden for which a medicine is indicated is no longer a national health concern; and in case of antimicrobials, if the resistance pattern has rendered a medicine ineffective etc.3

Specific Issues Deliberated During The Revision Process

The specific dimensions were considered during the deliberation by the Core- Committee for revising the NLEM, 2015 such as, dosage forms/ formulations; strengths of medicines; salts of active moieties of medicines; isomers/ analogues/ derivatives etc. of medicines; medicines in national health programmes; pack size of formulations; incremental innovation; formulations of modified release/ sustained release/ extended release etc., and improved or novel drug delivery systems.

Enforceability of NLEM

NLEM is a list of medicines prepared by the Ministry of Health and Family Welfare based on essentiality and made part of the Drugs Price Control Orders (DPCO), 2013 (DPCO 2013) in the form of first Schedule of the DPCO 2013. DPCO 2013 is an order issued by the Central Government having power under section 3 of the Essential Commodity Act, 1955 which enables it to fix the prices of essential bulk drugs and their formulations mentioned under the NLEM. The formulations which are included in NLEM i.e. first Schedule of the DPCO 2013 whether referred by generic name or brand are known as Scheduled Formulations. Any person acting in contravention of the DPCO 2013 is punishable under section 7 of the Essential Commodities Act, 1955, punishable with imprisonment for a term of not less than three months and may extend upto seven years. Where the person is convicted again the court may in addition to the penalty, direct the person to abstain from doing any business in essential commodities for a period not less than six months. Any company which is found acting in contravention of the DPCO 2013, the person responsible for the conduct of the business of such company shall be liable along with the company, for such contravention of the order.


Revision of NLEM in 2015 was based on the complex process in the light of fast changing concepts in medicines, treatment regimens, introduction of new technologies and incremental innovations in drug delivery systems and formulations, wide differences in medical practice pattern in the country, regional variations in health care system etc. NLEM has been made part of the DPCO 2013 which gives right to the Central Government to fix/regulate the prices of formulations listed therein.





The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions